First Patient Enrolled in Revita® Wound Care Study
We’re excited to announce the commencement of our second level 1 clinical study for Revita!
This level 1 randomized controlled trial will assess the safety and efficacy of Revita as a wound covering for diabetic foot ulcers (DFUs). Diabetes impacts 30 million people across the United States, and as many as 25% of diabetic patients will develop a DFU within their lifetime.1-2 Without proper treatment, DFUs commonly result in amputation, leaving the patient with a 50% chance of survival. 3-4
As the first placental membrane allograft to capture the complete intact membrane in a shelf-stable format, Revita is uniquely capable of addressing DFUs. Since the product was launched, Revita has shown excellent effectiveness as a wound covering for a broad range of wound types including DFUs. This study will build on that experience and demonstrate broader, clinically validated outcomes.
We are thrilled to have this trial underway and are continuing to invest in high quality outcomes data for the complete portfolio of StimLabs products.
More information on this study can be found press release.
MKTG 19- 004 Rev 01
1. American Diabetes Association. Statistics About Diabetes. 2018 Mar.2. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA2005;293:217–228pmid:1564454.3. Alexiadou, Management of Diabetic Foot Ulcers. 2012 Apr 20.4. Armstrong DG, Wrobel J, Robbins JM. Guest editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007;4:286–287pmid:18154621
share this article
You Might Also Like
Use of placental tissues has been recorded for over a century, beginning in 1910 as an allograft during skin transplantation...